Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...
Sage Therapeutics SAGE reported a loss of $3.37 per share for the third quarter of 2023, wider than the year-ago quarter’s loss of $2.31. The reported loss included restructuring expenses of $33.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results